Artiva Biotherapeutics
ARTV
49 hedge funds and large institutions have $319M invested in Artiva Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
85.34% more ownership
Funds ownership: 0% → 85.34% (+85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$114M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
+$27.3M |
| 3 |
VA
VR Adviser
New York
|
+$18.7M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$17.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$10.6M |
Top Sellers
ARTV Hedge Fund Activity: Q3 2024 in Review
49 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q3 2024, worth a combined $319M.
Buyers outnumbered sellers: 49 funds opened new ARTV positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $114M.
- 49 institutional investors held Artiva Biotherapeutics (ARTV) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $319M of Artiva Biotherapeutics stock for Q3 2024.
- 49 funds opened new Artiva Biotherapeutics positions in Q3 2024 and 0 closed out, a net change of +49 holders.
- The largest Artiva Biotherapeutics buyer in Q3 2024 was RA Capital Management, an estimated $114M added.
Based on aggregated 13F filings for Q3 2024.